 Konstantinos Arnaoutakis
Concepts (121)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 5 | 2018 | 643 | 1.200 |
Why?
| | Hematology | 3 | 2022 | 26 | 0.910 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 164 | 0.880 |
Why?
| | Medical Oncology | 3 | 2022 | 110 | 0.710 |
Why?
| | Neoplasms | 4 | 2018 | 1322 | 0.670 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2017 | 37 | 0.600 |
Why?
| | Bone Marrow | 2 | 2016 | 414 | 0.570 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2016 | 10 | 0.560 |
Why?
| | Anemia, Aplastic | 1 | 2016 | 12 | 0.560 |
Why?
| | Pancytopenia | 1 | 2016 | 40 | 0.540 |
Why?
| | Communication | 2 | 2016 | 265 | 0.510 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 134 | 0.510 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2015 | 101 | 0.500 |
Why?
| | Seminoma | 1 | 2013 | 4 | 0.490 |
Why?
| | Bone Marrow Neoplasms | 1 | 2014 | 15 | 0.480 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 169 | 0.480 |
Why?
| | Pyrazoles | 1 | 2015 | 110 | 0.480 |
Why?
| | Pyridines | 1 | 2015 | 137 | 0.470 |
Why?
| | Biopsy, Fine-Needle | 1 | 2014 | 116 | 0.470 |
Why?
| | Hodgkin Disease | 1 | 2014 | 51 | 0.470 |
Why?
| | Paralysis | 1 | 2013 | 9 | 0.460 |
Why?
| | Testicular Neoplasms | 1 | 2013 | 47 | 0.460 |
Why?
| | Spinal Cord Neoplasms | 1 | 2013 | 15 | 0.460 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 216 | 0.450 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 106 | 0.420 |
Why?
| | Bronchial Neoplasms | 1 | 2009 | 5 | 0.370 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 22 | 0.360 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 117 | 0.340 |
Why?
| | Aged | 11 | 2018 | 10060 | 0.290 |
Why?
| | Humans | 21 | 2022 | 54391 | 0.260 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 252 | 0.240 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 1300 | 0.230 |
Why?
| | Female | 11 | 2018 | 28471 | 0.230 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 1222 | 0.220 |
Why?
| | Radiography | 2 | 2013 | 526 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2016 | 1060 | 0.210 |
Why?
| | Middle Aged | 7 | 2018 | 13082 | 0.200 |
Why?
| | Integrative Medicine | 1 | 2018 | 9 | 0.160 |
Why?
| | Qualitative Research | 2 | 2018 | 326 | 0.160 |
Why?
| | Patients | 1 | 2018 | 53 | 0.160 |
Why?
| | Terminal Care | 1 | 2018 | 55 | 0.150 |
Why?
| | Keratins | 1 | 2017 | 33 | 0.150 |
Why?
| | Doxorubicin | 2 | 2017 | 259 | 0.150 |
Why?
| | Quality Improvement | 2 | 2016 | 245 | 0.150 |
Why?
| | Nanotubes | 1 | 2017 | 38 | 0.150 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 171 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 60 | 0.150 |
Why?
| | Silver | 1 | 2017 | 54 | 0.150 |
Why?
| | Drug Carriers | 1 | 2017 | 82 | 0.150 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 167 | 0.150 |
Why?
| | Education, Medical | 1 | 2018 | 104 | 0.140 |
Why?
| | Constipation | 1 | 2016 | 34 | 0.140 |
Why?
| | Mastication | 1 | 2016 | 7 | 0.140 |
Why?
| | Male | 8 | 2018 | 27347 | 0.140 |
Why?
| | Attitude to Health | 1 | 2018 | 226 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2013 | 119 | 0.140 |
Why?
| | Learning | 1 | 2018 | 171 | 0.140 |
Why?
| | Pyrroles | 1 | 2016 | 78 | 0.140 |
Why?
| | Gold | 1 | 2017 | 164 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2013 | 145 | 0.130 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 164 | 0.130 |
Why?
| | Carcinoma, Renal Cell | 1 | 2016 | 120 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2016 | 219 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 564 | 0.130 |
Why?
| | Computer Simulation | 1 | 2016 | 332 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2017 | 389 | 0.120 |
Why?
| | Factor VIII | 1 | 2014 | 29 | 0.120 |
Why?
| | ADAM Proteins | 1 | 2014 | 24 | 0.120 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 17 | 0.120 |
Why?
| | Reed-Sternberg Cells | 1 | 2014 | 2 | 0.120 |
Why?
| | HIV Seronegativity | 1 | 2014 | 3 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2016 | 197 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2016 | 5612 | 0.120 |
Why?
| | Plasma Exchange | 1 | 2014 | 33 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1090 | 0.120 |
Why?
| | Orchiectomy | 1 | 2013 | 38 | 0.120 |
Why?
| | Scrotum | 1 | 2013 | 34 | 0.120 |
Why?
| | Bronchoscopy | 1 | 2014 | 79 | 0.120 |
Why?
| | Indoles | 1 | 2016 | 289 | 0.120 |
Why?
| | Pain | 1 | 2016 | 405 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2013 | 225 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1141 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 323 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 500 | 0.100 |
Why?
| | Biopsy | 1 | 2014 | 692 | 0.100 |
Why?
| | Adult | 5 | 2016 | 14207 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2014 | 3431 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2013 | 645 | 0.090 |
Why?
| | Nausea | 1 | 2008 | 53 | 0.080 |
Why?
| | Morpholines | 1 | 2008 | 64 | 0.080 |
Why?
| | Vomiting | 1 | 2008 | 73 | 0.080 |
Why?
| | Survival Analysis | 1 | 2009 | 736 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2016 | 6459 | 0.080 |
Why?
| | Immunotherapy | 1 | 2009 | 264 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2009 | 805 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2016 | 302 | 0.060 |
Why?
| | Prognosis | 1 | 2009 | 2126 | 0.060 |
Why?
| | Accreditation | 1 | 2022 | 73 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 226 | 0.040 |
Why?
| | Coated Materials, Biocompatible | 1 | 2017 | 40 | 0.040 |
Why?
| | Spectrum Analysis, Raman | 1 | 2017 | 68 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 128 | 0.040 |
Why?
| | Genotype | 1 | 2018 | 600 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 4318 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 657 | 0.030 |
Why?
| | Autoantibodies | 1 | 2014 | 135 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 1551 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 248 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 693 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 2010 | 28 | 0.020 |
Why?
| | SEER Program | 1 | 2010 | 95 | 0.020 |
Why?
| | Antiemetics | 1 | 2008 | 35 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2008 | 172 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 426 | 0.020 |
Why?
| | Dexamethasone | 1 | 2008 | 435 | 0.020 |
Why?
| | United States | 1 | 2016 | 5208 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 1476 | 0.020 |
Why?
| | Adolescent | 1 | 2016 | 6900 | 0.020 |
Why?
| | Prospective Studies | 1 | 2008 | 2606 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 3210 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2008 | 1249 | 0.010 |
Why?
|
|
Arnaoutakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|